Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. by Patel, Katan et al.
Targeting of 5-aza-20-deoxycytidine residues by
chromatin-associated DNMT1 induces proteasomal
degradation of the free enzyme
Katan Patel1, Jacqueline Dickson1, Shahida Din1, Kenneth Macleod1, Duncan Jodrell2
and Bernard Ramsahoye1,*
1Breakthrough Research Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh
and 2Department of Oncology, University of Cambridge, Addenbrooke’s Hospital and Cancer Research UK,
Cambridge Research Institute (CRI),
Cambridge, UK
Received September 8, 2009; Revised March 2, 2010; Accepted March 5, 2010
ABSTRACT
5-Aza-20-deoxycytidine (5-aza-dC) is a nucleoside
analogue with cytotoxic and DNA demethylating
effects. Here we show that 5-aza-dC induces the
proteasomal degradation of free (non-chromatin
bound) DNMT1 through a mechanism which is de-
pendent on DNA synthesis and the targeting of
incorporated 5-aza-dC residues by DNMT1 itself.
Thus, 5-aza-dC induces Dnmt1 degradation in
wild-type mouse ES cells, but not in Dnmt [3a–/–,
3b–/–] mouse ES cells which express Dnmt1 but
lack DNA methylation (<0.7% of CpG methylated)
and contain few hemi-methylated CpG sites, these
being the preferred substrates for Dnmt1. We
suggest that adducts formed between DNMT1 and
5-aza-dC molecules in DNA induce a ubiquitin-E3
ligase activity which preferentially targets free
DNMT1 molecules for degradation by the prote-
asome. The proteasome inhibitor MG132 prevents
DNMT1 degradation and reduces hypomethylation
induced by 5-aza-dC.
INTRODUCTION
5-Aza-20-deoxycytidine (5-aza-dC, Decitabine) is a nucleo-
side analogue and DNA demethylating agent. Early
studies showed that treatment of cell lines with the
ribonucleoside analogue 5-azacytidine lead to a loss of
extractable DNA methyltransferase activity (1). It was
proposed that this was caused by the entrapment of main-
tenance DNA methyltransferase DNMT1 by 5-aza-dC
residues incorporated into the DNA. The mechanism of
action predicts that during synthesis the enzyme would
attack and attempt to methylate 5-aza-dC molecules
incorporated 50 to G residues and opposite methylated
CpG dinucleotides in the parent strand
(azaCpG:mCpG). However, because of the lack of a
proton at the N5 position of the aza-substituted pyrimi-
dine ring, the enzyme would not subsequently be released
by b-elimination (2). As DNMT1 is a highly processive
enzyme, this covalent entrapment of the enzyme would
lead to a significant loss of maintenance methyltransferase
activity and demethylation of the DNA. A recent study
used the FRAP (fluorescence recovery after photobleach-
ing) technique to provide evidence in support of this mech-
anism (3). The study demonstrated that the half-time of
fluorescence recovery (t1/2) after photo bleaching was 15 s
for DNMT1 protein, but recovery did not occur in cells
treated with 5-aza-dC. Furthermore, photoactivatable
DNMT1 (paGFP-DNMT1) did not dissociate from the
irradiated site in cells treated with 5-aza-dC indicating
that it had indeed been trapped.
Whilst the trapping mechanism has been the accepted
paradigm for explaining the demethylation induced by
5-aza-dC, a recent study showed that 5-aza-dC caused
the proteasomal degradation of DNMT1 through a
process that is not apparently dependent on its incorpor-
ation into DNA: the effect could not be abolished by prior
treatment of the cells with the DNA synthesis inhibitor
aphidicolin (4). The proteasomal degradation of
DNMT1 was shown to be dependent on the KEN box,
bromo-adjacent domain and nuclear localization domains
located in the N-terminus of the enzyme and was mediated
by APCCDH1/FZR1-catalysed polyubiquitinylation of
DNMT1(4).
Because two potential mechanisms limiting DNMT1
availability in response to 5-aza-dC have been uncovered,
it is not clear whether the hypomethylating effects of the
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drug are due to degradation of the DNMT1 enzyme, en-
trapment of it by 5-aza-dC residues in the DNA, or both.
In this report we have investigated the mechanism of the
5-aza-dC effect on DNMT1 degradation and find that,
contrary to the original report uncovering the DNMT1
degradation pathway, DNA synthesis is required. Our
data indicate that the DNMT1 degrading effects of
5-aza-dC are very sensitive to and dependent upon the
incorporation of 5-aza-dC into DNA. We provide
evidence that Dnmt1 itself triggers its own degradation
by attacking 5-aza-dC residues incorporated into the
DNA, and demonstrate that DNMT1 degradation con-
tributes to the hypomethylation induced by 5-aza-dC.
MATERIAL AND METHODS
Materials
5-Aza-dC (Decitabine), MG132, phosphodiesterase I,
alkaline phosphatase, Triton X-100, 5-methyl-2-
deoxycytidine (5mdC), 2-deoxycytidine (dC), 2-deoxy-
guanosine (dG) monohydrate and 2-deoxythymidine
(dT) monohydrate were all purchased from Sigma,
(Sigma, Gillingham, UK). Benzonase was purchased
from Merck (Merck, Nottingham, UK). HPLC grade
acetonitrile (MeCN), water and methanol were from
Rathburn (Walkerburn, UK). Mass spectrometry grade
formic acid was from BDH (BDH, Poole, UK).
Instrumentation
The HPLC system consisted of a Dionex 3000 Ultimate
series LC (Sunnyvale, CA, USA) connected to either the
photodiode array detector (Dionex) with the Foxy Jr.
fraction collector (Dionex) or a 4000 QTrap LC–MS/MS
mass spectrometer equipped with an orthogonal
electrospray ion source (Applied Biosystems, Foster
City, CA, USA). Data were acquired and processed with
Chromeleon 6.1 and Analyst 1.4 chromatography
manager software, respectively.
HPLC chromatographic and mass spectrometry conditions
For HPLC fractionation of nucleoside standards and di-
gestions of tritium labelled thymidine and 5-aza-dC DNA,
a LUNA C18 (150 4.6mm I.D.) and 3 mm particle size
(Phenomenex, Torrance, CA, USA) column was used. The
HPLC method used isocratic elution; mobile phase
solvent A was water with 50mM sodium phosphate pH
5 (98%) and mobile phase B was methanol (2%) with a
total run time of 40min. The column was set at a flow rate
of 0.8mlmin–1, a column temperature of 25C and an in-
jection volume of 50 ml. Alternatively, digested nucleosides
for global DNA methylation analyses were separated on a
Gemini C18 (150 2.0mm ID) and 3 mm particle size
(Phenomenex, Torrance, CA, USA) protected by a
Phenomenex Gemini C18 (4.0 2.0mm ID) and 3 mm
particle size guard cartridge. The HPLC method used
gradient elution; mobile phase solvent A was water with
0.1% formic acid and mobile phase B was acetonitrile with
0.1% formic acid. The initial mobile phase composition of
99% solvent A and 1% solvent B was maintained for
2min. Between 2 and 7min the percentage of mobile
phase B was increased to 40% and then back to the
initial mobile phase composition within 0.1min, with a
total time of 14min. The column was set at a flow rate
of 0.2mlmin–1 and a column temperature of 35C. Sample
volume of 5 ml was used for all LC–MS experiments. The
mass spectrometer was operated in positive electrospray
mode. The source temperature was 450C and a spray
voltage 3 kV was used. The collision gas pressure was
1.5mTorr. All analytes were optimized using the Analyst
software auto tune facility for MRM transitions.
Quantification was accomplished in multiple reaction
monitoring (MRM) mode by monitoring a transition
pair of m/z 242.1 (molecular ion)/126.1 (fragment ion)
for 5mdC and m/z 268.1/152.1 for dG, which was used
as an internal standard for the measurement, with a
dwell time of 100ms for each pair.
Cell culture, DNA isolation and cell lysate preparation
HCT116 and SW620 cell lines were cultured at 37C in a
5% CO2 incubator using an RPMI medium supplemented
with 10% fetal bovine serum (FBS, Invitrogen, Paisley,
UK). Mouse J1 (wild-type) and Dnmt[3a–/–, 3b–/–] ES
cell lines (5) and were cultured in Glasgow’s MEM/10%
FCS supplemented with non-essential amino acids,
pyruvate, b-mercaptoethanol and leukaemia inhibitory
factor (LIF). Cell lines were treated with 5-aza-dC
(Decitabine) ranging from 0.0005 to 10 mM, MG132
(10 mM) and aphidicolin (20mg/ml). Genomic DNA was
isolated from the above cells using QIAamp DNA mini kit
(Qiagen, West Sussex, UK), according to the manufactur-
er’s instructions. For cell lysate preparation fresh cells
(106–108 cells) in culture medium were resuspended in
1ml ice-cold PBS, centrifuged at 1000 g for 5min at
4C, and the supernatant was removed and discarded.
The pellet was resuspended in 100–400ml ice-cold RIPA
lysis buffer (150mM NaCl, 1% NP40, 0.5% (deoxycholic
acid), 0.1% SDS, 50mM Tris pH 7.0 and protease inhibi-
tor cocktail tablet (Roche, West Sussex, UK) and
incubated on ice for 10min. The lysate was centrifuged
at 12 000 g for 10min at 4C. The supernatants were
stored at –20C.
DNA hydrolysis
DNA hydrolysis was performed as previously described
(6). This method improves the recovery of 5-aza-dC
from DNA incorporated with 5-aza-dC because denatur-
ation of the DNA, is avoided which affects 5-aza-dC sta-
bility. Briefly, 250U Benzonase (Merck), 500mU
phosphodiesterase I (Sigma), 200U alkaline phosphatase
(Sigma) was added to 2.5ml of Tris–HCl buffer (pH 7.9,
20mM) containing 100mM NaCl and 20mM MgCl2.
Following the preparation of the DNA 25 ml of the
reaction mix was added to 1 mg of genomic DNA. The
DNA samples were digested for 6 h. A one-tenth
dilution was made of the digest with HPLC grade water
and injected into the LC–MS/MS system.
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Cell-cycle analysis
HCT116 cells were synchronized by blocking them at the
G1/S boundary. The cells were first grown in reduced
serum (RPMI/0.5% FBS) for 24 h, followed by growth
in aphidicolin (20mg/ml) and RPMI/10% serum for a
further 24 h. This effectively blocked the vast majority of
cells at the G1/S boundary. The block was released by
washing out the aphidicolin containing medium and
replacing it with normal RPMI/10% FBS. Cells were har-
vested and prepared for flow cytometry by trypsinization
to produce a mononuclear cell suspension, followed by
quenching of the trypsin with serum and resuspension of
the cells in PBS. After counting 106 cells were transferred
to 12 75mm polystyrene tubes, centrifuged and resus-
pended in 300 ml PBS. An amount of 700 ml ice cold
ethanol was added (drop wise) and the cells which were
allowed to fix on ice for 1 h. The cells were then resus-
pended in 250 ml PBS containing 5 ml of a 10mg/ml
solution of RNase A and 10 ml of a 1mg/ml solution of
propidium iodide and their fluorescence intensity was
measured in a flow cytometer at 488 nm.
Analysis of [5-methyl-3H]-Thymidine and 5-aza-[63H]-dC
from DNA
Cells were treated with 5-aza-[63H]-dC purchased from
Moravek Biochemicals (1mCi/ml, Brea, CA) or
[5-Methyl-3H]-thymidine (1mCi/ml, Perkin Elmer,
Bucks, UK). Subsequently the cells were incubated for
0.5, 2, 4 and 6 h or replaced in, after 2 h, 5-aza-[63H]-dC
or [5-Methyl-3H]-thymidine free medium and incubated
for 0.5, 2, 4 and 6 h. DNA was isolated as described
above. Aliquots were taken for DNA quantification,
using the Quant-it dsDNA kit (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions and liquid
scintillation (Beckman LS 5000 Liquid Scintillation
Counter).
Preparation of detergent-soluble and -insoluble fractions
After the designated drug treatments, Triton X-100
soluble and insoluble fractions were prepared by adding
gentle lysis buffer 200 ml (PBS+0.5% Triton X-100 with
protease inhibitor tablets) to cells in six-well plates. The
plates were left on a rocking platform for 30min at 4C.
The cell lysate was transferred and centrifuged at
13 000 rpm for 10min. The supernatant was collected as
the soluble fraction and the remaining pellet resuspended
in 50 ml of 1SDS loading buffer.
Immunoblotting
Equal amounts of protein for each sample were then
separated on 6–12% Bis–Tris acrylamide gels using
MOPS buffer and then transferred onto PVDF mem-
branes (Amersham, Buckinghamshire, UK). The blots
were blocked in TBS-T (10mM Tris–HCl, pH 8.0,
150mM NaCl, 0.1% Tween 20) containing 5% non-fat
milk and subsequently incubated with anti-DNMT1
(New England Biolabs, Herts, UK). Anti-CDH1/FZR1
mouse monoclonal was purchased from Genway. The
sheep anti-mouse Dnmt3a antibody (cross-reacting with
human DNMT3A) was raised in our laboratory. The
anti-DNMT3B antibody was purchased from Santa
Cruz. Anti Histone H4 antibody was purchased from
Millipore. Equal loading was confirmed by probing for
b-ACTIN (Cell Signalling), Ku70 (Abcam) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
Cell Signalling). Horseradish peroxidase conjugated sec-
ondary antibodies were detected using a
Chemiluminescent detection kit (Amersham).
siRNA experiments
RNA interference assay. CDH1/FZR1 small interfering
RNA (siRNA) smart pool and scrambled non-targeting
fluorescent control siRNA were obtained from
Dharmacon. HCT116 cells were transfected for 48 h with
100 nM siRNA using Lipofectamine 2000 (Invitrogen) fol-
lowing the manufacturers instructions. After 48 h, cells
were treated with 5-aza-dC (0.1 and 1 mM) for 12 h, and
cell extracts were subjected to western blot analysis.
Quantitative RT–PCR. Quantitive estimation of DNMT1
transcript levels was carried out using the primers and
conditions set out in Ghoshal et al. (4).
RESULTS
DNMT1 is degraded by the proteasome upon
treatment of 5-aza-dC
We exposed HCT116 cells to 1 mM 5-aza-dC for 10 h
(Figure 1A). A reduction in DNMT1 levels was
observed by 6 h and levels were massively reduced by
8 h, as assessed by western blotting for DNMT1 protein,
but there was no significant change in DNMT3A or
DNMT3B protein levels. Quantitative RT–PCR of
DNMT1 mRNA showed that the reduction in DNMT1
protein at 24 h was not caused by reduced transcription
(Figure 1B). We demonstrated that 5-aza-dC induced the
degradation of preformed DNMT1 protein by
pre-treating cells with the protein synthesis inhibitor
cycloheximide prior to exposure to 5-aza-dC
(Figure 1C). Cycloheximide reduces DNMT1 levels by ap-
proximately 50% at 6 h, indicating that DNMT1 protein
molecules have a half-life of approximately 6 h (Figure 1C,
lane 2). Addition of 5 mM 5-aza-dC resulted in a further
loss of DNMT1 protein (Figure 1C, lane 4). This can only
be explained by increased DNMT1 protein degradation as
DNMT1 protein synthesis had already been inhibited by
cycloheximide. Pre-treatment with the proteasome inhibi-
tor MG132 inhibited DNMT1 degradation induced by
5-aza-dC, suggesting that degradation occurred through
the proteasome (Figure 1D). As it has previously been
reported that the anaphase promoting complex (APC)
component CDH1/FZR1 is the ubiquitin ligase respon-
sible for marking DNMT1 for degradation, we knocked
down CDH1/FZR1 in HCT116 cells with siRNA and
determined the effectiveness of 5-aza-dC at inducing
DNMT1 degradation in these cells. Despite knockdown
of CDH1/FZR1 protein levels to 40% of the level seen in
control cells, we were unable to rescue the DNMT1 deg-
radation induced by 5-aza-dC (Figure 1E). These data do
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not argue against proteasomal degradation as being the
cause of DNMT1 loss in response to 5-aza-dC treatment,
but they cast doubt on whether CDH1/FZR1 is the ligase
responsible.
Degradation of DNMT1 is highly sensitive to 5-aza-dC
We investigated the sensitivity of cells to DNMT1 degrad-
ation induced by 5-aza-dC by exposing HCT116 cells to
various concentrations of the drug for 12 and 24 h
(Figure 2A). No loss of DNMT1 was observed with
0.0005 mM 5-aza-dC at 24 h, but significant loss was
detected in cells exposed to 0.0025 mM. SW620 cells were
approximately 10 times less sensitive to the
DNMT1-degrading effects of 5-aza-dC. At 24 h a signifi-
cant reduction was observed at 0.01mM and DNMT1
protein was undetectable at 0.025 mM (Figure 2B). In
both cell lines there appeared to be a 5-aza-dC concentra-
tion threshold at which DNMT1 depletion was induced
rather than a graduated effect of the drug. The reason for
the differences in sensitivity of the two cell lines to
5-aza-dC induced DNMT1 degradation is not known.
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Figure 1. 5-Aza-dC induces the proteasomal degradation of DNMT1. (A) Western blot of DNMT1, DNMT3A, DNMT3B and KU70 (loading
control) after treatment of HCT116 cells with 1 mM 5-aza-dC. Degradation is induced by 6 h of treatment. (B) Quantitative RT–PCR of DNMT1
relative to 18S RNA in HCT116 cells exposed to 0.1 and 1 mM 5-aza-dC for 24 h. (C) Western blot of DNMT1 levels and GAPDH (loading control)
after treatment of HCT116 cells with cycloheximide (protein synthesis inhibitor) and 5-aza-dC. The DNMT1-lowering effect of 5-aza-dC in
cycloheximide treated cells indicates that 5-aza-dC acts post-transcriptionally and post-translationally to lower DNMT1 levels. (D) Western blot
of DNMT1 and ACTIN (loading control) to show the effect of a 12-h treatment with 5-aza-dC and MG132 (10 mM). The MG132 treatment was
commenced 2 h before 5-aza-dC to ensure that proteasome blockade was effective prior to 5-aza-dC exposure. (E) CDH1/FZR1 was knocked down
with siRNA in HCT116 cells before being exposed to 0.1 and 1mM 5-aza-dC. Controls include a mock transfection control (no siRNA), to control
for untoward effects of the transfection reagent, and a fluorescent nonsense siRNA, to ensure that transfection had taken place and to exclude
non-specific effects. The graphs demonstrate that CDH1/FZR1 was knocked down to 40% of the level seen in the control cells.
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The cell lines have similar cell-cycle characteristics and
grow at the same rates (18-h doubling time, data not
shown).
We looked to see whether there was a correlation
between DNMT1 loss and hypomethylation.
Surprisingly, in HCT116 cells the threshold effect
observed for DNMT1 loss was not observed for
demethylation (measured by mass spectrometry) which
exhibited more of a graduated dose dependent effect
(Figure 2C). Interestingly, very low doses of 5-aza-dC
(0.0025 and 0.005 mM) caused significant loss of
DNMT1 protein but had negligible effects on DNA
methylation levels. It appeared therefore that effective
maintenance methylation could take place in the
presence of significant reductions in DNMT1 protein,
either because other DNA methyltransferases (the
de novo methyltransferases DNMT3A and DNMT3B)
were still present and could support methylation, or
simply because maintenance methylation by DNMT1 can
occur effectively when DNMT1 levels are low. The capacity
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for low levels of DNMT1 to maintain methylation was
previously reported by Egger et al. (7). The fact that
SW620 cells were 10 times less sensitive to the
DNMT1-depleting effects of 5-aza-dC, but were equally
sensitive to its demethylating effects (Figure 2D), indicated
that it was the level of incorporation of 5-aza-dC into
DNA, rather than the degree of DNMT1 degradation,
which was the most important factor determining the
amount of demethylation induced.
To determine whether low dose 5-aza-dC might have
had a more significant effect on DNA methylation over
a longer time course through its effect on DNMT1 levels
we performed a separate experiment in which HCT116
cells were exposed to 5-aza-dC for 5 days, replenishing
the drug containing medium every 12 h. Here, the effects
on DNMT1 protein levels were maintained (Figure 2E),
but surprisingly the effects of low dose 5-aza-dC on
demethylation were actually less at 5 days than they were
at 24 h (Figure 2F). The effects of the highest dose of
5-aza-dC (1 mM) were as expected, methylation levels
being slightly lower (36%) at 5 days than they were at
24 h (42%).
5-aza-dC is stably incorporated into DNA and
incorporation is reduced but not abolished by aphidicolin
To investigate whether the induction of DNMT1 degrad-
ation by 5-aza-dC was dependent on incorporation of
5-aza-dC into the DNA we first needed to demonstrate
that 5-aza-dC was incorporated into the DNA as
5-aza-dC, and not some metabolite of it. Previous
studies have shown that the tritium label in 5-aza-
[6-3H]dC is transferred to the DNA (8), but no studies
have demonstrated chromatographically that the label is
still present within the incorporated 5-aza-dC molecules.
5-aza-dC is highly labile, being sensitive to acid and base,
and this may explain why its direct incorporation into
DNA has not yet been shown directly. We used a rapid
DNA hydrolysis technique using low temperature (37C)
conditions and reverse-phase HPLC (see methods) to
confirm the presence of 5-aza-[6-3H]dC residues in the
DNA (Figure 3A). We were also interested to know
whether 5-aza-dC might be actively excised from the
DNA. A time course experiment demonstrated a gradual
increase in 5-aza-[6-3H]dC in the DNA (Figure 3B), and
levels were maintained when the 5-aza-[6-3H]dC label was
removed (Figure 3C). These data demonstrate that there is
no rapid excision of 5-aza-[6-3H]dC from the DNA.
We went on to determine the extent to which the DNA
polymerase inhibitor aphidicolin could inhibit incorpor-
ation of the 5-aza-dC label into the DNA. As expected,
prior exposure of the cells to aphidicolin (20mg/ml for
24 h) reduced 5-aza-[6-3H]dC incorporation dramatically,
but incorporation was not completely abolished, falling to
10% of the levels seen without aphidicolin treatment
(Figure 3D). Aphidicolin also caused a substantial reduc-
tion in [5-methyl-3H]thymidine incorporation, reducing it
to 3% of the level seen without aphidicolin treatment
(Figure 3D). Thus, DNA synthesis is markedly reduced
but is not abolished by aphidicolin.
The degradation of DNMT1 is dependent on DNA
synthesis
To investigate whether the proteasomal degradation of
DNMT1 was dependent upon incorporation of 5-aza-dC
into DNA, we determined whether DNMT1 degradation
could be inhibited by pre-treatment of HCT116 and
SW620 cells with aphidicolin. We examined the effects of
aphidicolin over a range of different concentrations of
5-aza-dC. We found that aphidicolin suppressed
DNMT1 degradation induced by low doses of 5-aza-dC,
but degradation induced by higher doses (1 mM) of
5-aza-dC could not be suppressed (Figure 4A and B). As
DNA synthesis is reduced but not completely inhibited by
aphidicolin (Figure 3D) we conclude that the effect of
5-aza-dC on DNMT1 degradation is indeed dependent
on DNA synthesis. At low concentrations of 5-aza-dC
pre-treatment with aphidicolin is sufficient to reduce
5-aza-dC incorporation below the level required to
trigger degradation. However at high concentrations of
5-aza-dC (1 mM) pre-treatment with aphidicolin has no
effect on the DNMT1 degradation because sufficient
5-aza-dC is still incorporated into the DNA to induce
DNMT1 degradation.
We were intrigued to see that the DNMT1 protein
appeared to have been substantially lost from the entire
culture, whilst our results pointed to a mechanism
whereby DNMT1 loss occurred as a result of 5-aza-dC
incorporation during DNA synthesis. A synthesis
specific effect would have affected approximately
30–40% in the culture but DNMT1 protein should have
been detectable in those cells that were not in DNA syn-
thesis. However, if the expression of DNMT1 protein was
itself tightly restricted to the DNA synthesis phase of the
cell cycle, this might explain why DNMT1 loss was so
complete. It has previously been shown that DNMT1
transcription is largely restricted to synthesis (9), but to
our knowledge no studies have looked at protein levels
during the cell cycle. To look at the expression of
DNMT1 protein during different phases of the cell cycle
we synchronized HCT116 cells by serum starvation (24 h)
followed by aphidicolin treatment in the presence of 10%
serum. This synchronized the cells at the G1/S phase
boundary. DNMT1 levels were monitored by western
blotting following release of the aphidicolin block, and
cell-cycle progression was followed by flow cytometry
using the DNA stain propidium iodide. Figures 4C
and D show that DNMT1 is markedly reduced in G1,
highly induced in S-phase (0.5–8 h) and reduced again in
G2 (8–12 h). Thus, in protein extracts made from
unsynchronized cells, most of the DNMT1 protein
comes from the cells that are actively undergoing DNA
synthesis.
We investigated whether any of the reduction in
DNMT1 expression observed in 5-aza-dC treated cells
might be attributable to 5-aza-dC induced changes in the
cell cycle. We observed a small reduction in the number of
cells undergoing synthesis in unsynchronized HCT116
culture exposed to 5-aza-dC, particularly at doses
greater than 0.1 mM (Figure 4E), but even cells treated
with 10 mM 5-aza-dC retained 30% of the culture in
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synthesis (compared with 45% untreated). Thus the
modest reduction in the proportion of cells in S phase
cannot explain the dramatic loss of DNMT1 protein
from these cultures.
5-aza-dC-induced degradation of DNMT1 is DNA
methylation dependent
As DNMT1 degradation was dependent on 5-aza-dC
incorporation into DNA, we speculated that DNMT1
might be required to attack 5-aza-dC residues in the
DNA before DNMT1 degradation was triggered. To test
this we needed conditions in which 5-aza-dC would be
incorporated into the DNA without being targeted by
DNMT1. As DNMT1 targets hemi-methylated DNA in
preference to unmethylated DNA, and was recently shown
to be preferentially trapped by 5-aza-dC molecules
incorporated into a hemi-methylated substrate (10), we
reasoned that the effects of 5-aza-dC would be less
pronounced on a background of very low genomic DNA
methylation as the number of hemi-methylated CpG
target sites would also be low. We have previously
shown that late passage Dnmt[3a–/–,3b–/–] mouse ES cells
retain Dnmt1 but are severely demethylated (11). We con-
firmed this difference using the mass spectrometry tech-
nique to quantify DNA methylation (Figure 5A). We
tested the effects of 5-aza-dC on Dnmt1 levels in
wild-type (70% of CpG methylated) and severely
hypomethylated Dnmt[3a–/–,3b–/–] mouse ES cells
(<0.7% of CpG methylated). We found that 5-aza-dC
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caused marked Dnmt1 degradation in the wild-type cells
but not in the mutant cells (Figure 5B). As the
Dnmt[3a–/–,3b–/–] mouse ES cells have markedly reduced
DNAmethylation but retain Dnmt1, it is clear that Dnmt1
does not target the unmethylated CpG sites in these cells
(else they would be methylated), but targets and maintains
only the small number of hemi-methylated CpG that
remain. These data therefore indicate that the targeting
of Dnmt1 to 5-aza-dC residues in hemi-methylated DNA
is required before Dnmt1 degradation is induced.
A recent study indicated that in HCT116 cells the tar-
geting of DNMT1 to 5-aza-dC residues causes DNA
damage as assessed by the number of foci containing
histone H2AX (12). We therefore asked whether DNA
damage itself might be the trigger for the proteasomal
degradation of DNMT1. We looked at the effects of
gamma irradiation (Supplementary Figure S1) and UV
irradiation (Supplementary Figure S2), but neither of
these treatments induced loss of DNMT1, despite the in-
duction of p53 by gamma irradiation. DNMT1 degrad-
ation also occurred in p53 deficient HCT116 cells
(Supplementary Figure S3) ruling out a function for p53
in the degradation pathway.
Chromatin bound DNMT1 is relatively resistant to
DNMT1 degradation
The observation that DNA methylation could be relative-
ly well maintained in the presence of a low dose of
5-aza-dC despite significant degradation of DNMT1
(Figure 2A) prompted us to investigate whether
DNMT1, which is a nuclear protein (13,14), might exist
in two separate nuclear pools. We postulated that within
the nucleus there might be a small chromatin bound pool
associated with PCNA (15) that was actively engaged in
maintenance methylation and which could become cova-
lently linked to 5-aza-dC during synthesis, and a much
larger soluble pool that was not actively engaged in main-
taining methylation but which was preferentially degraded
in the proteasome following 5-aza-dC treatment. In the
absence of 5-aza-dC both forms would be detectable by
western blotting, as the chromatin bound form would dis-
sociate in denaturing SDS lysis buffer. After treatment
with 5-aza-dC some chromatin-associated DNMT1
would become irreversibly linked (by covalent attach-
ment) to 5-aza-dC molecules in the DNA, to an extent
which was dependent on the dosage of the 5-aza-dC.
This would lead to a dose dependent reduction in DNA
methylation levels. The linked (trapped) DNMT1 would
not be detectable by western blotting as it would not
migrate out of the gel onto the membrane, but any
DNMT1 that was not trapped (because of low 5-aza-dC
dosage) would be free to continue maintenance methyla-
tion and would be detectable by western blotting.
We extracted protein from cells using a gentle lysis
buffer so as to preserve any weak association between
DNMT1 and the chromatin (see ‘Materials and
Methods’ section). After centrifugation the cellular
proteins were separated into soluble (the supernatant)
and insoluble fractions (the chromatin bound pellet) and
re-suspended in 1 SDS loading buffer. We found that
most DNMT1 was in the soluble fraction, and after
5-aza-dC treatment, DNMT1 was preferentially lost
from this fraction (Figure 6A). At 0.005 mM 5-aza-dC
DNMT1 was lost from the soluble fraction but was
retained in the insoluble fraction, and at higher doses
DNMT1 was progressively lost from the insoluble
fraction. To demonstrate that we had fractioned the
DNMT1 as envisaged we looked at the levels of
GAPDH which is a cytoplasmic protein, explaining why
it was hardly detected in the chromatin pellet, but was
abundant in the soluble fraction. By contrast Histone
H4, a chromatin protein, was only detectable in the
pellet. Our findings indicate that whilst DNMT1 is
required to target the DNA before the signal for
DNMT1 degradation is induced, the mechanism that
degrades DNMT1 or that marks it for degradation is
induced globally within the nucleus, with the soluble
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form of DNMT1 being more susceptible to degradation
than the chromatin bound form. Interestingly, rescue of
the DNMT1 protein by pre-treatment of the cells with
MG132 changed the distribution of DNMT1 markedly
(Figure 6A, lower panel). At low doses of 5-aza-dC
(0.005 mM) treatment with MG132 caused the DNMT1
protein to appear in the soluble fraction (as expected),
whereas at higher doses of 5-aza-dC (0.1 and 1 mM)
pre-treatment with the same dose of MG132 caused the
protein to reappear in the chromatin bound fraction (as-
terisks, Figure 6A). This result is most probably explained
by the rescued DNMT1 homing to increased amounts of
hemi-methylated DNA in chromatin. Hemi-methylated
DNA is the preferred natural substrate of the enzyme
and 5-aza-C treatment results in high levels of
hemi-methylated DNA (16). Consistent with this idea,
MG132 caused a marked reduction in the degree of
hypomethylation induced by 5-aza-dC (Figure 6B), pre-
sumably because the rescued DNMT1 was able to
restore full methylation to a proportion of the
hemi-methylated sites induced by trapping. Because of
the relative ineffectiveness of low dose 5-aza-dC at
inducing demethylation (even when DNMT1 degradation
has been induced) we suggest that dose-dependent
trapping is the primary mechanism whereby 5-aza-dC
induces hypomethylation. As this also triggers the
proteasomal degradation of free non-chromatin
associated DNMT1 the cell has no way of compensating
for the hypomethylation induced by trapping. The
ameliorating effects of MG132 on 5-aza-dC induced
hypomethylation indicate that trapping on its own
would be relatively ineffective at inducing
hypomethylation.
DISCUSSION
In this report we show that incorporation of 5-aza-dC
during DNA synthesis causes the proteasomal
degradation of DNMT1. The phenomenon is very sensi-
tive to 5-aza-dC incorporation, occurring at much lower
doses than are commonly used for inducing
demethylation. The high sensitivity of cells to
5-aza-dC-induced DNMT1 degradation explains why, at
high doses of 5-aza-dC, the DNA synthesis inhibitor
aphidicolin fails to inhibit the effect. Aphidicolin does
not completely inhibit DNA synthesis. Therefore, at
high doses of 5-aza-dC, sufficient drug is still incorporated
into DNA to induce the effect. These findings explain why
the authors of the original report which identified the
5-aza-dC-induced DNMT1 degradation pathway
concluded that the effect must in some way have been
independent of DNA synthesis (4). The lowest dose of
5-aza-dC used in their study was 0.1 mM (range 0.1–
10 mM). The ameliorating effect of DNA synthesis inhib-
ition was only seen at doses of 0.1 mM and below in our
study.
5-aza-dC-induced degradation of Dnmt1 does not occur
in severely hypomethylated mouse Dnmt[3a–/–,3b–/–] ES
cells. As DNA methylation is essentially absent in these
cells, this indicates that targeting of incorporated 5-aza-dC
molecules by Dnmt1 (a process known to be dependent on
the presence of hemi-methylated target sites) is also essen-
tial before Dnmt1 degradation takes place. Our data are
therefore consistent with a mechanism whereby, on the
incorporation of 5-aza-dC into DNA, the chromatin
bound enzyme attacks any 5-aza-dC residues that are
incorporated diagonally opposite 5mC residues in the
parent strand, and attempts to methylate them.
Trapping of the enzyme ensues and the covalent
complexes formed activate the proteasomal degradation
of the free enzyme (Figure 7). Adduct formation
between DNMT1 and DNA could also explain the
DNMT1 degradation induced by SGI-1027, a compound
which has been shown to compete with
S-adenosylmethionine in the methylation reaction (17).
Interference with S-adenosylmethionine binding would
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prevent transfer of the methyl group after covalent adduc-
tion of the DNMT1 protein to C6 of the cytosine ring had
taken place. The mechanism of action of DNMT1 predicts
that failure to transfer the methyl group to C5 would
prevent release of the enzyme by b-elimination, mimicking
the effect of 5-aza-dC-induced entrapment (2).
The mechanism whereby the DNMT1-DNA adducts
induce DNMT1 degradation has not been elucidated in
this study. The study by Ghoshal et al. (4) provided
evidence that the ubiquitin-E3 ligase CDH1/FZR1, a com-
ponent of the anaphase promoting complex, was respon-
sible for ubiquitinylation of DNMT1. However we were
unable to prevent DNMT1 destruction by knocking down
CDH1/FZR1 using siRNA (Figure 1E). Our results can
not exclude CDH1/FZR1 as being the E3 ligase respon-
sible for targeting DNMT1 for destruction as we can
never be certain that our knockdown, though effective,
was effective enough. Ghoshal et al. (4) also indicated
that the N terminus of DNMT1 was crucial for the deg-
radation. We have not tested this but evidence from trans-
genic mice indicates that it is likely to be correct. The
shorter oocyte specific isoform of Dnmt1 (Dnmt1o) is
driven by a separate promoter and is identical to the
somatic form (Dnmt1s) apart from the fact that it lacks
the extreme 118N-terminal amino acids (14). When
Dnmt1o protein was engineered to be driven by the en-
dogenous Dnmt1s promoter in mice, late embryos hetero-
zygous for both proteins had Dnmt1o protein levels that
were five times higher than Dnmt1s levels. Thus under
conditions of equal transcription Dnmt1o undergoes less
protein degradation presumably because it lacks the
N-terminal sequence. These data indicate that the N
terminal amino acids are crucial for controlling Dnmt1
protein levels even in the absence of 5-aza-dC (18).
The DNMT1 degrading effects of 5-aza-dC can occur at
very low doses of the drug, and at these doses there
appears to be little or no effect on demethylation. We
can not exclude the possibility that some hypomethylation
has occurred at a limited number of specific sites, but at a
global level demethylation is not obvious. We can also not
rule out the possibility that DNMT3A and DNMT3B
compensate for methylation losses due to mild DNMT1
inhibition. However Egger et al. (7) found that treatment
of HCT116 cells which are hypomorphic for DNMT1 with
siRNA molecules against DNMT1 caused a lowering of
DNA methylation levels. As these cells express both
DNMT3A and DNMT3B, these enzymes were clearly
not able to compensate for methylation losses caused by
DNMT1 depletion. We favour the possibility that, as
DNMT1 degradation does not affect all DNMT1 mol-
ecules (the chromatin bound enzyme which is actively
engaged in methylation is relatively spared), there is
enough residual DNMT1 activity to support maintenance
methylation in the presence of low dose 5-aza-dC.
Our data indicate that most of the cellular DNMT1 is
soluble (in the nucleoplasm) and it would appear that cells
have considerably more DNMT1 than they need for main-
taining DNA methylation. This is also suggested by the
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results of Egger et al. (7) who found that DNA methyla-
tion levels are near normal in HCT116 cells which are
hypomorphic for DNMT1. These cells express a truncated
form of DNMT1 which is present at 20% of the normal
wild-type levels of the protein. DNA methylation levels
are also normal in heterozygous Dnmt1+/– ES cells and
Dnmt1 mutated heterozygous mice despite the heterozy-
gotes having lower levels of Dnmt1 protein (19). The
DNMT1 protein that is not actively engaged in mainten-
ance methylation may fulfil other non-enzymatic func-
tions. Studies have shown that apart from maintenance
methylation DNMT1 is also involved in mis-match
repair (20) the prevention of apoptosis (21) and the
mitotic phase of the cell cycle (22).
As the induction of hypomethylation correlates better
with the 5-aza-dC dose than the DNMT1 level (as assessed
by western blot) we suggest that it is trapping of chroma-
tin bound DNMT1 molecules by 5-aza-dC which is the
primary cause of hypomethylation. Degradation of free
DNMT1 exacerbates the effect by preventing the full
methylation of hemi-methylated sites created by
trapping. As the degradation of DNMT1 occurs at low
dosage, our findings raise the possibility that there may be
distinct S-phase specific biological effects of 5-aza-dC
which are operative at dosages which would not ordinarily
be toxic, but which might collaborate with other estab-
lished therapies to modulate and increase the effectiveness
of cancer therapy.
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